Table 2 Treatment characteristics from SPRINT-2 [17]
A. Efficacy and Discontinuation Rates | ||||||
|---|---|---|---|---|---|---|
| Â | Non-Black Cohort | Black Cohort | ||||
| Â | PR48 | BOC/RGT | BOC/PR48 | PR48 | BOC/RGT | BOC/PR48 |
|  | (N = 311) | (N = 316) | (N = 311) | (N = 52) | (N = 52) | (N = 55) |
Sustained virologic response,% (95% confidence interval) distribution | 40.2 (34.7–45.9) | 66.8 (61.3–71.9) | 68.5 (63.0–73.6) | 23.1 (12.5–45.9) | 42.3 (28.7–56.8) | 52.7 (38.8–66.3) |
Beta (123.00, 183.02) | Beta (212.7, 105.85) | Beta (216.12, 99.43) | Beta (123.00, 183.02) | Beta (212.7, 105.85) | Beta (216.12, 99.43) | |
Probability of discontinuation before Week 24 for reasons other than futility, n/m (%) | 46/311 (14.8) | 49/316 (15.5) | 46/311 (14.8) | 10/52 (19.2) | 12/52 (23.5) | 8/55 (14.5) |
Probability of discontinuation after Week 24 for reasons other than futility, n/m (%) | 25/173 (14.5) | 20/225 (8.9) | 42/232 (18.1) | 6/17 (33.3) | 3/27 (11.1) | 8/33 (22.9) |
Probability of failing futility rule at Week 24, n/m (%) | 92/265 (34.7) | 42/267 (15.7) | 33/265 (12.5) | 25/42 (59.5) | 13/40 (32.5) | 14/47 (29.8) |
Probability of being assigned and completing 28Â weeks of treatment, n (%) | NA | 147 (46.5) | NA | NA | 15 (28.8) | NA |
B. Side Effects | Combined Cohorts | |||||
| Â | PR48 | BOC/RGT | BOC/PR48 | |||
|  | (N = 363) | (N = 368) | (N = 366) | |||
Anemia, n (%) | 107 (29.5) | 182 (49.5) | 180 (49.2) | |||
Erythropoietin use, n (%) | 87 (24.0) | 159 (43.2) | 159 (43.4) | |||
Mean duration of anemia, Days | 128.3 | 107.9 | 145.0 | |||
Mean duration of erythropoietin use, days | 121.4 | 93.5 | 156.4 | |||